West Virginia University
Welcome,         Profile    Billing    Logout  
 297 Trials 
1340 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Feinberg, Judith
BIRCH, NCT05668780: Buprenorphine Integration Research and Community Health

Active, not recruiting
N/A
20
US
NIATx Coaching
Yale University, National Institute on Drug Abuse (NIDA), West Virginia University
Opioid Use Disorder, HIV Infections, Hepatitis C
05/26
05/26
Cooper, Brenda W
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
10/25
01/27
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
10/25
11/26
NCT04194840: Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Recruiting
N/A
20
US
physical therapy consult, Cognitive Assessment, Cancer Aging Research Group (CARG) assessment, Medication Review, Nutrition assessment, Laboratory studies, Patient satisfaction questionnaire, Physician Questionnaire, Patient follow-up questionnaire
Case Comprehensive Cancer Center
Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant
12/24
12/26
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40
McCarthy, Philip L
CALGB-100104, NCT00114101: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Checkmark Data presentation from CALGB 100104 study for NDMM at ASCO
Jun 2017 - Jun 2017: Data presentation from CALGB 100104 study for NDMM at ASCO
Checkmark P3 data
May 2012 - May 2012: P3 data
Active, not recruiting
3
460
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Placebo Administration
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
12/12
02/25
NCT03333486: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Active, not recruiting
2
31
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation
Roswell Park Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
08/23
08/24
NCT03925532: Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Completed
2
30
US
Denosumab, AMG 162, AMG-162, Prolia, Xgeva
Roswell Park Cancer Institute, Amgen
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
11/22
11/22
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Recruiting
2
300
US
Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
07/24
07/24
NCT02650986: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Active, not recruiting
1/2
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
03/21
07/32
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Hodder, Sally
TRUST, NCT04875702: Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Recruiting
4
650
US
Allopurinol, Aloprim, Zyloprim, Naproxen 250 MG, Prophylaxis, Colchicine 0.6 mg, Colchicine 1.2 mg, Flare, Naproxen 500 Mg, Prednisone 40 mg
Massachusetts General Hospital, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Gout
09/28
10/28
NCT05524532: Effects of Immulina TM Supplements with PASC Patients

Recruiting
3
120
US
Immulina TM, Spirulina, Placebo
University of Mississippi Medical Center, National Institute of General Medical Sciences (NIGMS)
Post Acute COVID-19 Syndrome
10/25
12/25
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Active, not recruiting
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

Active, not recruiting
N/A
15178
US
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
SARS-CoV2 Infection
04/25
05/25
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing

Recruiting
N/A
30000
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/27
12/27
Saul, J Philip
NCT04474223: Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Recruiting
3
1300
Canada, US
Dexamethasone, IVIG
NYU Langone Health
AVB - Atrioventricular Block, Fetal AVB
08/26
10/26
Altice, Frederick
NCT04417946: Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)

Completed
N/A
227
US
PrEP messages, Heath messages
Yale University, Substance Abuse and Mental Health Services Administration (SAMHSA)
Pre-Exposure Prophylaxis, Hiv, Men
04/23
04/23
HARAPAN II, NCT03089983: Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

Completed
N/A
1702
RoW
Methadone, Isoniazid, Rifapentine
Yale University, University of Malaya, National Institute on Drug Abuse (NIDA)
Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis, Hepatitis
04/24
04/24
IMPACT, NCT04927091: Integrating Addiction Treatment and HIV Services Into Primary Care Clinics in Ukraine

Completed
N/A
1458
RoW
Integration of HIV and PWID services
Yale University, Ukrainian Institute on Public Health Policy, National Institute on Drug Abuse (NIDA)
Hiv, Opioid-use Disorder
06/24
06/24
MATLINK, NCT04947475: Project Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community

Active, not recruiting
N/A
835
RoW
SBIRT
Yale University, Ukrainian Institute on Public Health Policy, AFEW Kyrgyzstan, AFI - Act For Involvement, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, HIV Infections, Tuberculosis, Hepatitis C, Hepatitis B, Depression, Syphilis
07/24
07/24
RS-ART, NCT06541028: Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)

Not yet recruiting
N/A
135
RoW
Rapid-Start ART (RS-ART)
Yale University, National Institute of Mental Health (NIMH), Fogarty International Center of the National Institute of Health
Hiv, Drug Use
08/26
08/26
BIRCH, NCT05668780: Buprenorphine Integration Research and Community Health

Active, not recruiting
N/A
20
US
NIATx Coaching
Yale University, National Institute on Drug Abuse (NIDA), West Virginia University
Opioid Use Disorder, HIV Infections, Hepatitis C
05/26
05/26
ExMAT CA, NCT05579470: Expanding Medication-Assisted Therapies in Central Asia

Recruiting
N/A
900
US, RoW
NIATx
Yale University, Den Sooluk Nuru, Institute for International Health and Education, Global Health Research Center of Central Asia, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
12/26
12/26
NCT05910268: Peru Decentralized HIV Care

Recruiting
N/A
1450
US, RoW
NIATx + ECHO
Yale University, National Institute of Allergy and Infectious Diseases (NIAID)
HIV
07/28
07/28
Loeb, David M
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT01804634: Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Recruiting
2
60
US
Cyclophosphamide, cytoxan, Fludarabine, Flu, low dose total body irradiation, TBI, Melphalan, Mel, Tacrolimus, tacro
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Refractory and/or Relapsed Metastatic Solid Tumors
01/27
01/30
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT03465592: Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Recruiting
1/2
39
US
Nivolumab, BMS-936558, MDX1106, ONO-4538
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
01/27
03/29
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Konrad, Peter
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
Realini, Tony
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27
Harrison, Michael R
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
RadiCal, NCT04071223: Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Recruiting
2
134
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo
National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
10/25
10/25
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
NCT05156424: A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer

Recruiting
1/2
24
Europe
Exercise
Kira Murphy, Irish Research Council, University of Pittsburgh Medical Center, Waterford Instituate of Technology
Exercise, Prostate Cancer
03/23
03/23
NCT06556147: A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

Active, not recruiting
1
144
RoW
VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose), VXB-241 480 mcg (High Dose), VXB-241, Placebo, Arexvy 120 mcg
Vicebio Australia Proprietary Limited
Healthy Volunteers
08/25
05/27
Magnamosis, NCT02043392: First-in-human Study of Feasibility and Safety

Completed
N/A
5
US
Magnamosis, Magnetic Compression Anastomosis
Michael Harrison, University of California, San Francisco
Intestinal Anastomosis Complication
11/17
11/17
MAGNAP, NCT02431507: Magnetic Apnea Prevention() Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety

Recruiting
N/A
10
US
Magnap, Magnetic apnea device
Michael Harrison
Obstructive Sleep Apnea
12/25
12/26
APEX-AV, NCT05318092: Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism

Completed
N/A
122
US
AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE
Angiodynamics, Inc.
Pulmonary Embolism, Acute Pulmonary Embolism
01/24
01/24
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
TRIO CAP, NCT05017935: RADIANCE Continued Access Protocol

Active, not recruiting
N/A
300
US
Renal Denervation
ReCor Medical, Inc.
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
12/28
12/28
Uy, Geoffrey L
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
NCT03701308: Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Active, not recruiting
2/3
670
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Uproleselan, GMI-1271
National Cancer Institute (NCI)
Acute Myeloid Leukemia
12/25
12/25
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
2
50
US
BL-8040, Leukapheresis, Hematopoietic cell transplant
Washington University School of Medicine, BioLineRx, Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
04/18
04/23
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
2
64
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
02/25
02/25
BLAST MRD AML-2, NCT04284787: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Active, not recruiting
2
60
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
06/23
01/26
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
07/26
07/26
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Withdrawn
2
48
NA
Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis
Washington University School of Medicine
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
09/26
07/28
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Withdrawn
2
35
NA
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Active, not recruiting
2
17
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
07/26
07/26
MyeloMATCH, NCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH ( Screening Trial)

Recruiting
2
2000
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Echocardiography, EC, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/29
05/29
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/29
07/29
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
110
US
CIML NK Cell Infusion, CD3+ T Cell Product Infusion
Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute
Acute Myeloid Leukemia
10/28
10/28
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated
1
1
US
Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone
Washington University School of Medicine, Sanofi
Multiple Myeloma
12/22
01/24
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Terminated
1
4
US
ApoGraft
Washington University School of Medicine, Cellect Biotechnology
Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant
12/22
12/22
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Completed
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
04/24
05/24
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Recruiting
1
54
US
WU-CART-007
Washington University School of Medicine, Wugen, Inc.
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
04/26
04/26
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Recruiting
N/A
50
US
Skin punch biopsy, Peripheral blood draw
Washington University School of Medicine
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
04/25
04/25
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Recruiting
N/A
165
US
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Washington University School of Medicine, Notable Labs
Acute Myeloid Leukemia, Myelodysplastic Syndromes
01/25
01/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Wisniewski, Stephen R
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27
Rezai, Ali
NCT05603312: A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

Completed
1/2
14
US
AAV-GAD Dose 1, AAV-GAD Dose 2, Sham Surgery
MeiraGTx, LLC
Parkinson Disease
09/24
09/24
NCT05469009: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Recruiting
1
15
US
Aducanumab, Aduhelm, Exablate Model 4000 Type 2, Focused Ultrasound, Lecanemab, Leqembi
Ali Rezai, InSightec
Mild Cognitive Impairment, Alzheimer Disease 1
07/29
07/29
DBS OUD, NCT03950492: Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Active, not recruiting
N/A
4
US
Deep Brain Simulator
West Virginia University, National Institute on Drug Abuse (NIDA), Medtronic
Opioid-Related Disorders
12/22
12/26
NCT06612788: Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD)

Active, not recruiting
N/A
5
US
Exablate Model 4000 Type 2.0/2.1
West Virginia University, National Institute on Drug Abuse (NIDA), InSightec
Opioid Use Disorder
07/24
04/25
NCT04197921: Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD) And/or Other Substance Use Disorders (SUDs)

Recruiting
N/A
29
US
Exablate Model 4000 Type 2.0/2.1
InSightec
Opioid-use Disorder, Substance Use Disorders
12/25
12/26
NCT06218706: LIFU for Treatment for Refractory Opioid Use Disorder

Recruiting
N/A
34
US
Low Intensity Focussed Ultrasound
Ali Rezai, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
10/26
03/28
NCT06485687: Low Intensity Focused Ultrasound for Binge Eating Disorder

Recruiting
N/A
15
US
LIFU Neuromodulation
Ali Rezai
Binge-Eating Disorder
12/26
12/27
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Recruiting
N/A
150
US
Blood Brain Barrier (BBB) Disruption, ExAblate Neuro
InSightec
Alzheimer Disease
12/25
12/25
NCT05997030: Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

Recruiting
N/A
15
US
low intensity focused ultrasound (LIFU)
Ali Rezai
Alzheimer Disease
09/25
09/25
NCT05976672: Machine Learning Technology in Predicting Relapse and Implementing Peer Recovery Intervention Before Drug Use Occurs

Recruiting
N/A
500
US
PRSS (Peer Recovery Support Specialist)
West Virginia University
Substance Abuse Disorder
04/28
04/28
Jacobson, Geraldine
NCT03716193: Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

Recruiting
N/A
40
US
Oxygen
West Virginia University, West Virginia Clinical and Translational Science Institute, Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Skin Lesion, Skin Cancer, Skin Melanoma, Tumor Skin
07/24
07/24
COMET, NCT02926911: Comparing an Operation to Monitoring, With or Without Endocrine Therapy () Trial For Low Risk DCIS

Active, not recruiting
N/A
997
US
Surgery, Active Monitoring
Alliance Foundation Trials, LLC., Patient-Centered Outcomes Research Institute, Duke University, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, New York University, Washington University School of Medicine
DCIS, Ductal Carcinoma in Situ
07/28
07/28
Oral, Elif A
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Active, not recruiting
4
10
US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalized Lipodystrophy
10/24
04/25
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Active, not recruiting
2
4
US
Metreleptin
University of Michigan, Amryt Pharma
Lipomatosis, Multiple Symmetrical
04/24
04/25
LEAP, NCT05088460 / 2021-000138-33: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Terminated
2
20
Europe, US, RoW
REGN4461, mibavademab, Matching Placebo
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Familial Partial Lipodystrophy, Metabolic Abnormalities
12/23
04/24
NCT02404896: Expanded Access Metreleptin Study

Available
N/A
US
Metreleptin, MyaLept
University of Michigan
Familial Partial Lipodystrophy
 
 
STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)

Recruiting
N/A
264
US
RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham
Morphic Medical Inc., Biostatistical Consulting, Inc.
Diabetes type2, Obesity
12/25
12/26
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT03087253: The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Recruiting
N/A
500
US, RoW
University of Michigan
Lipodystrophy (Genetic or Acquired, Non HIV)
03/31
03/31
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting
N/A
100
Europe, US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy, Partial Lipodystrophy
10/31
10/31
RADIANT, NCT05544266: Rare and Atypical Diabetes Network

Recruiting
N/A
2000
US
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
09/30
09/30
Strickland, Stephen
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
ASC4START, NCT05456191: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Active, not recruiting
3
571
Europe, Canada, US, RoW
Asciminib, ABL001, Nilotinib
Novartis Pharmaceuticals
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
03/25
07/31
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Active, not recruiting
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
VNX-101-01, NCT06533579: Gene Therapy for B-Cell Acute Lymphoblastic Leukemia

Recruiting
1/2
26
US
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101
Vironexis Biotherapeutics Inc.
B-cell Acute Lymphoblastic Leukemia
06/26
09/31
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Hourglass Jul 2024 - Dec 2024 : Preliminary data r/r/ AML
Terminated
1/2
40
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
07/24
07/24
 

Download Options